Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Responses to Influenza Vaccine in Healthy Volunteers
NCT02385123Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of influenza virus vaccine inactivated in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of Subjects Achieving Seroconversion at Day 28 and Percentage of Subjects With Pre-vaccination Titer <1:40 at Day 0. Started Apr 2015; status: terminated.
02
Drugs
influenza virus vaccine inactivated
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02385123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02385123.